Literature DB >> 12425501

Complement and immunoglobulin levels in serum and ascitic fluid of patients with spontaneous bacterial peritonitis, malignant ascites, and tuberculous peritonitis.

Bulent Yildirim1, Nurzen Sezgin, Ramazan Sari, Alper Sevinc, Fatih Hilmioglu.   

Abstract

BACKGROUND: We determined complement and immunoglobulin levels in ascitic fluid and serum of 47 patients with spontaneous bacterial peritonitis, malignant ascites, or tuberculous ascites.
METHODS: Paracentesis was done to confirm the underlying cause of ascites. Biochemical, hematologic, and microbiologic investigations were also done.
RESULTS: The highest serum and ascitic fluid C3 and C4 levels and ascitic fluid IgM, IgA, and IgG levels were found in patients with tuberculosis. Ascitic fluid C3 level was found to be higher in the tuberculous group than in the patients with spontaneous bacterial peritonitis or malignant ascites. Ascitic fluid C4 levels were higher in patients with tuberculosis than in those with spontaneous bacterial peritonitis.
CONCLUSION: We believe that further studies of the in vivo kinetics of immunoglobulins and complement in ascitic fluid of various causes are necessary for a better understanding of the host defense mechanisms of these fluids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12425501

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Diagnosis of spontaneous bacterial peritonitis in infants and children with chronic liver disease: A cohort study.

Authors:  Mortada H F El-Shabrawi; Ola El-Sisi; Sawsan Okasha; Mona Isa; Sayed Abou Elmakarem; Iman Eyada; Zainab Abdel-Latif; Gamal El-Batran; Naglaa Kamal
Journal:  Ital J Pediatr       Date:  2011-05-21       Impact factor: 2.638

2.  Antibody-mediated depletion of immunosuppressive factors from ovarian carcinoma-associated ascites for investigation of paracrine versus autocrine effects.

Authors:  E Brencicova; S S Diebold
Journal:  J Immunol Methods       Date:  2017-01-31       Impact factor: 2.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.